Genotyping Assay Market

The global genotyping assays market is projected to reach USD 44.60 billion by 2031, up from USD 24.29 billion in 2026, at a CAGR of 12.9%. Market growth is driven by technological advances in DNA sequencing, the rising prevalence of genetic disorders, greater adoption of personalized medicine, and the growing use of genotyping in drug discovery and development. In parallel, rising demand for bioinformatics solutions, expanding genomic research, and advances in high-throughput testing technologies are expected to further support market expansion.

The global genotyping assays market comprises established life science and genomics companies, including Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN N.V. (Germany), Roche Diagnostics (Switzerland), and Merck KGaA (Germany), among others. These companies compete through comprehensive assay and reagent portfolios, advanced sequencing and molecular analysis technologies, product innovation, and strategic collaborations. Other prominent participants, including Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Agilent Technologies (US), and Revvity, Inc. (US), are strengthening their positions through investments in genomic research, diagnostic solutions, and advanced laboratory technologies. Continued innovation in genotyping platforms, reagents, and data analysis solutions is expected to shape the competitive landscape over the forecast period.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific is a leading provider of genotyping assays, molecular biology reagents, and analytical instruments. Its portfolio includes TaqMan SNP Genotyping Assays, custom genotyping assays, Applied Biosystems real-time PCR systems, and reagents for genetic variation analysis. The company supports applications in genetic research, drug metabolism studies, disease research, and pharmacogenomics. Its extensive assay catalog, established laboratory technology platforms, and integrated workflow solutions strengthen its position in the genotyping assays market.

Illumina, Inc. (US)

Illumina is a major player in the genotyping assays market, offering both microarray- and sequencing-based technologies for analyzing genetic variation. Its portfolio includes Infinium genotyping arrays, the Global Screening Array, the Global Diversity Array, sequencing reagents, and associated data analysis solutions. These technologies support population genomics, genome-wide association studies, pharmacogenomics, precision medicine research, and disease-risk assessment. The company's high-throughput platforms, customizable assay content, and established genomics ecosystem strengthen its competitive position.

QIAGEN N.V. (Germany)

QIAGEN is a leading supplier of molecular testing solutions, sample preparation technologies, and nucleic acid analysis products. Its portfolio includes PCR-based assays, molecular biology reagents, DNA extraction solutions, and instruments for genetic analysis and molecular diagnostics. The company supports research and clinical applications with integrated sample-to-result workflows, enabling laboratories to perform molecular testing and investigate genetic variation. Its established presence in molecular diagnostics, sample preparation, and life science research underpins its participation in the genotyping assays market.

Danaher Corporation (US)

Danaher Corporation participates in the genotyping assays market through its life sciences and diagnostics businesses, which include molecular biology and genomics technologies. Through its operating companies, the group provides instruments, reagents, and analytical solutions for nucleic acid analysis, molecular diagnostics, and genetic research. Its capabilities in laboratory automation, advanced diagnostics, and life science technologies support a range of applications in genetic analysis and disease detection. The company's broad technology portfolio and global commercial presence strengthen its position across the broader genomics and molecular testing ecosystem.

Market Ranking

The global genotyping assays market is dominated by established life science and genomics companies, with Thermo Fisher Scientific Inc., Illumina, Inc., Danaher Corporation, and QIAGEN N.V. estimated to account for approximately 45% to 55% of global market revenues. Based on the company-level estimates provided, Thermo Fisher Scientific and Illumina hold leading positions, supported by extensive assay portfolios, established technology platforms, and broad customer bases across research and clinical applications. Competitive differentiation is increasingly driven by assay accuracy, throughput, automation,technological innovation, and the ability to support genomic research and precision medicine applications.

Other prominent participants include Roche Diagnostics (Switzerland), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), and Revvity, Inc. (US). These companies compete with specialized molecular analysis technologies, laboratory reagents, testing services, and integrated research solutions. Oxford Nanopore Technologies plc (UK), Pacific Biosciences of California, Inc. (US), and Standard BioTools Inc. (US) also contribute to the competitive landscape with sequencing and advanced genomic analysis technologies. The remaining market comprises specialized assay developers, genomic testing service providers, and niche technology companies that compete through product innovation, application-specific solutions, and collaborations with pharmaceutical companies, diagnostic laboratories, and research institutions.

Related Reports:

Genotyping Assay Market by Product (Reagents & Kits, Instruments, Bioinformatics), Technology (PCR, NGS, Capillary Electrophoresis, Microarray), Application (Diagnostics, Agricultural Biotechnology), Competition, End User, Region – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]